Tagged with ARM

USA Blue-chip drug makers holding USD 200 billion in cash, mostly overseas, will start investing more of it in mergers and acquisitions (M&A) after President Trump’s tax overhaul slashed the cost of spending the money in the US, debt-ratings firm Moody’s predicts. The ratings firm names Amgen, Pfizer, Gilead, and Celgene…

Pharma Digital health startups raised over USD six billion in equity financing in 2016, representing a five-year compound annual growth rate of 32 percent and the fledgling industry segment already boasts at least eight unicorns with a combined value exceeding USD 15 billion. Most interesting of all, however, is the constellation…

UK Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by 2022. However, despite possessing the innovators, the infrastructure and the coverage, the UK’s thriving vaccine industry risks being blown off…

UK Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and meet current health needs. Lundbeck is now focused on four key CNS areas: depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.…

UK Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains why the momentum is right for the UK to lead the way in sustainable healthcare and how it can remain…

Portugal Hailing from the Dominican Republic, Silvia Guichardo brings a fresh perspective as well as both US and Iberian experience to GSK Portugal. Six months into her role as general manager, Guichardo highlights GSK’s historic commitment to Portuguese patients, new therapeutic areas for 2019, and the unsung importance of leading a…

Spain Lucas Sigman, director general of Chemo, a leader in the research, development and manufacture of finished dosage forms and the active pharmaceutical ingredient arm of Insud Pharma, highlights the 40 years of expertise of the company in manufacturing for generic players globally and discusses how the recent EUR 30 million…

Portugal Filipe Paias, general manager for Baxter International Portugal, illustrates the organizational change Baxter has undergone in the past three years, in both process, strategy, and reputation. In Portugal, Baxter is the market leader in several therapeutic areas, and Paias outlines the plan to build upon this success while consistently adapting…

UK Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates about working for a Japanese pharmaceutical company. He says that at Otsuka, people are encouraged to think for themselves, be…

UK As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical industry and the patients who rely on it are under serious threat from Brexit” Erik Nordkamp, Pfizer Erik Nordkamp, the…

Portugal Nelson Pires provides an insightful update on Portugual’s pharmaceutical market evolution as well as Jaba Recordati’s ambitious Portuguese affiliate. Pires shares that diversification is one technique of navigating the market, introduces their expansion into a new therapeutic area, and explains the affiliate’s new venture into Nigeria. Would you be able…

India One issue grinding the gears of the Indian pharmaceutical industry over recent years has been quality compliance. With a number of pharma manufacturers the recipients of warning letters from the US FDA, increased regulatory scrutiny has caused some consternation, but also progress in quality standards across the board. “I see…